Theracryf Plc · LSE:TCF
Theracryf — Evgen Pharma — Investor Presentation (February 2022)
13 slides from Theracryf's investor presentation, February 2022
Slide 1: Harnessing The Power of Sulforaphane
Harnessing The Power of Sulforaphane February 2022
Slide 2: Confidentiality and important notice
THIS PRESENTATION (AS DEFINED BELOW) IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA
Slide 3: Evgen - A Clinical Stage Drug Development Company
Evgen - A Clinical Stage Drug Development Company Focus on breast cancer, glioma and other cancers SFX-01 has three molecular targets, STAT 3, Nrf2 and SHP2 • Capital efficient, virtual, listed on AIM (LSE: EVG), focus: oncology and inflammation • 275m shares in issue • Developing a new class of pha
Slide 4: Recent Achievements
Recent Achievements mBC Commencement of pre-clinical collaboration with the University of Manchester and The Christie Hospital. Generate data to optimise positioning of SFX-01 in breast cancer treatment following promising Phase 2a clinical data. Out license market average $19m up front, $144m total
Slide 5: Management and Board
Management and Board Dr Huw Jones Richard Moulson Barry Clare CEO CFO Chairman Over 30 years’ experience of Qualified chartered accountant with Former main Board member of Boots leadership in public and private R&D- over 20 years experience working as a Company plc and Chairman UHSM based companies
Slide 6: Medical and Scientific Advisors
Medical and Scientific Advisors Dr Mary Stuart Dr Sacha Howell Professor Rob Clarke Senior oncology physician. Consultant Medical Oncologist at Professor of Breast Biology, University Previously Global Clinical Christie Foundation Trust of Manchester Leader/medical Science Director at Clinical Senio
Slide 7: Pipeline
Pipeline bd Qg on A Qf Queen Mary LOY University of London Juntade Andalucia... UNIVERSITA The Christie ‘Consejrade Salud y Familias DELL'AQUILA
Slide 8: SFX-01 Can Be Life-changing
SFX-01 Can Be Life-changing • Diagnosed age 40 ER+ Her2- early Breast Cancer • Received surgery, chemotherapy and tamoxifen • After 5 years diagnosed with pleural nodules • Enrolled into Phase 2a trial May 2017 – tamoxifen + SFX-01 • Objective response to treatment, very well tolerated, able to cont
Slide 9: Glioblastoma
Glioblastoma • Glioma is the most common form of brain tumour affecting around 5 per 100,000 people. The more severe, grade IV classification, glioblastoma, is a very serious form of brain tumour representing 45% of all cases. • Very poor life expectancy, the five-year survival of the severe grades
Slide 10: GBM Pre-clinical POC: in vivo U87MG, orthotopic
GBM Pre-clinical POC: in vivo U87MG, orthotopic Dr Claudio Festuccia - University of L’Aquila, Abruzzo Colapietro et al 2021
Slide 11: GBM Pre-clinical POC – in vitro validation
GBM Pre-clinical POC – in vitro validation Dr Euphemia Leung, Professor Bruce Baguley, University of Auckland, NZ Leung et al, 2021
Slide 12: Juvenile Myelomonocytic Leukaemia (JMML)
Juvenile Myelomonocytic Leukaemia (JMML) • A rare, aggressive and difficult to treat form of blood cancer that predominantly affects young children. The only effective treatment for most patients is allogeneic hematopoietic stem cell transplantation (HSCT). • Preclinical data has demonstrated that S
Slide 13: Evgen Pharma Plc enquiries
Evgen Pharma Plc enquiries@evgen.com www.evgen.com